FRONTIER BIOTECHNOLOGIES Inc.

News

   
Home>Media

Potential first-in-class dual-target siRNA drug candidate FB7033 shows promising preclinical results in MASH

Nanjing, China, May 31, 2026 — Frontier Biotech announced today the presentation of preclinical data for its first-in-class dual-target small interfering RNA (siRNA) drug candidate FB7033 at the EASL Congress 2026, in both poster and poster tour formats. EASL Congress is one of the most influential ...
  • 2026-05-31  19:04:53
details>

Frontier Biotech Showcases FB7023, a Novel Dual-Target siRNA Drug Candidate for the Treatment of ASCVD

NANJING, China, May 29, 2026 — Frontier Biotech today announced the presentation of preclinical data of FB7023, a dual-target small interfering RNA (siRNA) drug candidate, at the 20th Oriental Congress of Cardiology (OCC 2026), a leading academic conference in the cardiovascular field in ChinaFB7023...
  • 2026-05-29  16:13:09
details>

Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics

Frontier Biotechnologies Inc. (hereinafter referred to as “Frontier Biotech” or “the Company”) has entered into an exclusive licensing agreement with GSK, a global biopharma company. Under the terms of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture, and commerciali...
  • 2026-02-23  17:20:01
details>

Frontier Biotech's FIC, Dual-Target siRNA Drug Candidate FB7011 Brings Potential New Treatment Options for IgA Nephropathy

From September 17 to 20, 2025, the 18th International IgA Nephropathy Symposium (IIgANN 2025) was held in Prague, Czech Republic. At the conference, Frontier Biotech presented, via an oral presentation, the first set of preclinical data of its self-developed, potentially first-in-class dual-target s...
  • 2025-09-21  18:18:40
details>

Frontier Biotechnologies Partnered with XinHua Medical Products to bring revolutionary treatment for Cytomegalovirus Infection GANCIL® in China

10 November, 2023: Frontier Biotechnologies Inc. (Frontier Biotech) has partnered with Keyuan Xinhai (Beijing) Medical Products, to introduce GANCIL® (Valganciclovir Hydrochloride Tablets), a groundbreaking treatment option for cytomegalovirus (CMV) infection in China. This collaboration marks ...
  • 2023-11-14  09:22:23
details>

Aikening® New Promising Clinical Data Presented at the European AIDS Conference Preliminary Data Indicate that Aikening® Could Improve Immune Recovery Function of Immunological Non-Responders (InRs)

The 19th European AIDS Conference (EACS 2023) held in Warsaw, Poland in October 2023 witnessed a groundbreaking announcement by Frontier Biotechnologies Inc. The latest clinical trial results of Aikening®, a revolutionary treatment for people with HIV who have incomplete immune reconstitution, ...
  • 2023-11-05  09:19:40
details>

Frontier Biotechnologies Receives US FDA Clearance for Manufacturing Site Inspection

Frontier Biotechnologies is proud to announce that its wholly-owned subsidiary, Sichuan Frontier Biopharmaceutical Co., Ltd., has successfully obtained clearance from the U.S. Food & Drug Administration (FDA) for its manufacturing site inspection. This significant achievement confirms Sichuan Fr...
  • 2023-10-31  09:17:14
details>

Frontier Biotechnologies is the Award Winner of the Prestigious “24th China Patent Gold Awards"

July 21, 2023, the China National Intellectual Property Administration officially announced the list of winners awarded the “24th China Patent Awards”. Frontier Biotechnologies Inc. is awarded the Gold Award for the development of a novel HIV antiretroviral drug, which is a fusion inhibitor and a pe...
  • 2023-07-24  09:23:09
details>

Frontier Biotechnologies ranked in the list of “Top 30 Innovative Chinese Biopharmaceutical Enterprises for Small Molecule Drugs”

On June 28, 2022, Frontier Biotech (stock code "688221.SH") was ranked top 30 for the third consecutive year during the “Top 100 Innovative Chinese Biopharmaceutical Enterprises in 2022”
  • 2023-06-29  09:18:40
details>

Aikening® (albuvirtide) Granted Marketing Authorisation by the Ministry of Health in the Republic of Kazakhstan for the Treatment of HIV-1

Frontier Biotechnologies announced it obtained approval for Aikening® (albuvirtide for injection), the first long-acting fusion inhibitor treatment for HIV, from the Ministry of Health in the Republic of Kazakhstan. Aikening® is indicated to be used in combination with other antiretroviral...
  • 2023-06-09  13:38:09
details>

Aikening® (albuvirtide) Launched in Malaysia

Frontier Biotechnologies and Pahang Pharmacy have signed a partnership agreement for the supply, distribution and marketing of Aikening® in Malaysia. Aikening® is now available in Malaysia.Frontier Biotechnologies announced in September 2022 that the National Pharmaceutical Regulatory Agen...
  • 2023-03-16  09:21:15
details>

Good News | Frontier Biotech’s exclusive patented Product AIKENING® successfully renewed its contract with the National Essential Drug List

On January 18, 2023, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the National Medical Insurance, Labour Injury Insurance and Maternity Insurance Essential Drug List (2022) [hereafter referred to as the National Essential Drug List (2022...
  • 2023-01-19  13:48:02
details>

Develop Innovative Therapies to Better Human Lives

Frontier Biotechnologies Inc.（Nanjing）
Medicalinfo@frontierbiotech.com
jubao@frontierbiotech.com
Adverse events report mailbox：pv@frontierbiotech.com
Copyright © 2016 Corporation All Rights ReservedFrontier Biotechnologies Inc.
Full Prescribing Information | Introduction for Use | About Frontier

This site is for informational purposes only
and is intended for Healthcare Professionals.

Are you a Healthcare Professional?

I am a licensed Healthcare Professional I am a Patient or Caregiver